Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.

Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis. Abstract Text:

Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis. Publishing Authors By Initials

For similar peptides: intercellular signaling peptides and proteins: cytokines: monokines: tumor necrosis factor-alpha research abstracts see: peptides: intercellular signaling peptides and proteins: cytokines: monokines: tumor necrosis factor-alpha research

PUBMED ID PMID:

MEDLINE DATE:

Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Archives of dermatology

VOLUME: 137

Page Numbers: 784-5

Journal Abbreviation: Arch Dermatol

ISSN: 0003-987X

DAY: 17

MONTH: Jun

YEAR: 2001

Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372433

Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis. Keywords Mesh Terms:

KEYWORDS: Tumor Necrosis Factor-alpha

MESH TERMS: immunology

Chemical & Substance for Abstract: Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis. Information

Substance Name: TNFR-Fc fusion protein

Registry Number: 185243-69-0

Grant and Affiliation Information for Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.

AFFILIATION: Istituto Dermopatico dell'Immacolata, Via Monti di Creta 104, 00167 Rome, Italy.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Arch Dermatol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis Related Publications

• Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.
• Can cognitive-behavioral therapy help patients with vitiligo?
• Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions.
• Evidence for the association of human papillomavirus infection and cutaneous squamous cell carcinoma in immunocompetent individuals.
• Identification of categories at risk for high quality of life impairment in patients with vitiligo.
• Measuring the health status of patients with vascular leg ulcers and the burden for their caregivers.
• Performance of the self-administered psoriasis area and severity index in evaluating clinical and sociodemographic subgroups of patients with psoriasis.
• The health impact of pemphigus vulgaris and pemphigus foliaceus assessed using the Medical Outcomes Study 36-item short form health survey questionnaire.
• The impact of changes in clinical severity on psychiatric morbidity in patients with psoriasis: a follow-up study.